Canada Allows Professionals In Training To Use Psilocybin
The decision, announced Tuesday, marks the latest step in Canada’s path towards the legalization of psilocybin.
Since August 2020, Canada’s Health Minister has granted 14 exemptions to access psilocybin therapy, mainly for patients dealing with end-of-life distress.
“Health Canada now rightfully acknowledges that clinician experience with psychedelic medicines is an important part of their training. Therapists having psychedelic experience are able to more deeply empathize with patients and understand their experience,” said Bruce Tobin, founder and Board Chair of TheraPsil, a nonprofit working for patient access to psilocybin in Canada.
The UK To Begin First-Ever Clinical Trials On DMT For Depression
Clinical trials on the hallucinogenic drug DMT for the treatment of depression are expected to start in January.
According to The Guardian, the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) gave the green light to the
Imperial College of London, in partnership with neuropharmaceutical research company Small Pharma, to begin the trials.
DMT, a strong, short-acting hallucinogenic compound, remains illegal in the UK as in most countries around the globe. It is best known as the active ingredient in ayahuasca, a hallucinogenic drink traditionally used as a spiritual medicine in shamanic ceremonies among indigenous communities in South America.
Entheon Biomedical Announces DMT Drug Supply Agreement with Psygen Labs
- Completion of Initial DMT Research Drug Batch and Exercise of Warrants
Vancouver Canada based Entheon Biomedical Corp. (CSE: ENBI) (FSE: 1XU1), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply agreement with Psygen Labs Inc. Under the terms of the Agreement, Psygen will supply Entheon with non-GMP and GMP (good manufacturing practice) quality N,N-dimethyltryptamine drug substances (“
DMT”) for upcoming formulation, preclinical, clinical, and post-approval commercialization phases under the European Medicines Agency (EMA) regulatory framework. On November 27, 2020, Psygen successfully completed the production of a non-GMP DMT research batch for delivery to the Company’s Contract Research Organization, CHDR’s partner pharmacy. The non-GMP DMT research batch will be shipped to CHDR upon receipt of Psygen’s export perm